MedTrace Logo

Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

NCT04582981 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2021-10-26

No results posted yet for this study

Summary

A randomized, controlled phase II clinical trial of Fruquintinib combined with Raltitrexed versus Fruquintinib monotherapy in patients with advanced colorectal cancer who had failed second-line or above standard chemotherapy

Conditions

  • Advanced Colorectal Carcinoma

Interventions

DRUG

Fruquintinib and raltitrexed

Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w

DRUG

Fruquintinib

Fruquintinib 5mg qd monotherapy

Sponsors & Collaborators

  • Shanxi Province Cancer Hospital

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Weijian Guo · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-28
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04582981 on ClinicalTrials.gov